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Abstract
Drug repurposing (or drug repositioning) is an innovative way to find out the 
new indications of a drug that already exists in the market with known therapeutic 
indications. It offers an effective way to drug developers or the pharmaceutical 
companies to identify new targets for FDA-approved drugs. Less time consump-
tion, low cost and low risk of failure are some of the advantages being offered with 
drug repurposing. Sildenafil (Viagra), a landmark example of a repurposed drug, 
was introduced into the market as an antianginal drug. But at present, its use is 
repurposed as drug for erectile dysfunction. In a similar way, numerous drugs are 
there that have been successfully repurposed in managing the clinical conditions. 
The chapter would be highlighting the various drug repurposing strategies, drugs 
repurposed in the past and the current status of repurposed drugs in the orphan 
disease therapeutics along with regulatory guidelines for drug repurposing.
Keywords: drug repurposing, drug repositioning, orphan drug, orphan disease,  
a rare disease, regulatory guidelines
1. Introduction
Despite rapid advancement in science and technology, translating these benefits 
for care and management of human diseases remains a far slower process than 
expected. Pharmaceutical industries, research and development (R&D) sectors are 
facing multifold challenges for taking out any new drug in the market including 
higher attrition rates, long time span and regulatory restrictions [1]. It takes $2 to 
$3 billion money and about 13–15 years for developing any new drug in the market 
with a low success rate of approximately 2% only [2, 3]. Drug development process 
involves six stages: (i) compound screening and identification of lead compound; 
(ii) preclinical study; (iii) investigational new drug (IND) application for taking 
approval to conduct trial in humans, only if preclinical data of the drug is found to 
be shows effective and safe in animals; (iv) clinical study (phase 1, 2 and 3 clinical 
trials); (v) new drug application (NDA) if the drug is found to be safe and effective 
in phase 3 clinical trials; and (vi) post marketing surveillance (PMS) for safety moni-
toring. However, drug repurposing consists of four stages only: (i) selection of target 
compound; (ii) clinical trial (phase 2 and 3); (iii) NDA application and (iv) PMS 
(Figure 1). Thereby’ drug repurposing is a trending way to reduce the effort, cost 
and time at every step involved in drug development and thus provides an option to 
bring the new drugs into the market at relatively low investments (Figure 1) [3].
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1.1 Drug repurposing
‘Drug repurposing’ (or ‘drug repositioning’) is an effective way to find new 
targets or new indications of any drug that is already FDA approved and existing in 
the market. It is an excellent alternative over the de novo drug development process 
which is relatively time consuming and money involved procedure [4]. Since the data 
including drug efficacy, safety, bioavailability, route and formulation of administra-
tion, pharmacokinetic and pharmacodynamic (PK-PD) profile, toxicological data 
and associated adverse effects, are well known with already approved drugs. Thus, 
the evaluation process for drug candidates gets facilitated with drug repurposing and 
drug enters the clinical market for new therapeutic indications. Also, drug repurpos-
ing reduces the risk of development failure into the market, thus reducing the cost 
of the overall drug development process. At present, in the U.S approximately 30% 
of newly FDA approved drugs are repurposed only [5]. History witnessed numerous 
drug candidates that have been repurposed either opportunistic or serendipitous. 
Sildenafil is one of the blockbusters in the history of drug repurposing. Sildenafil, 
a phosphodiesterase type 5 (PDE5) inhibitor, was introduced in the market in the 
1980s by Pfizer for the treatment of coronary artery disease (CAD), hypertension 
and angina pectoris. During phase-1 trials of sildenafil, it was observed that the 
patients suffered from marked penile erection. In 1988, the drug was repurposed and 
approved by FDA for erectile dysfunction in the US market after the drug failed to 
prove its efficacy in phase-2 trials in angina patients [6]. Another big hit example is 
thalidomide. In 1957, the drug was developed by German pharmaceutical company 
named Grünentha for treatment of motion sickness in pregnant women. Soon the 
drug was withdrawn from the market as its use lead to serious birth defects (mal-
formations of the limbs) and death in approximately 10,000 children in around 46 
countries. Subsequently in 2006, the drug was re-approved by FDA for the treatment 
of multiple myeloma [4]. In the 1960s, amantadine was developed as an antiviral 
drug to treat influenza infections. After a few years, a patient who was suffering from 
Parkinson’s disease (PD) had taken amantadine for her flu infection. It was seen that 
the patient was having improvement in her PD symptoms after taking amantadine. 
From there, it has been concluded that the drug can be used in treating neurological 
disorders. Years later, amantadine received FDA approval for treatment of PD [7].
Figure 1. 
Phases in drug development.
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1.2 Off-label use of drugs
“Off-label drug use (OLDU)” defines to prescribe the drug beyond the con-
ditions for which the drug is holding the license for its market authorization. 
More specifically, off-label means using a drug for indications, dosage form, 
dose strength, route of administration or in that patient age group which are not 
approved by FDA [8]. FDA approves a drug to market only if it shows to be effec-
tive and safe in preclinical as well as clinical studies, refers to as “on-label drug use”. 
However, OLDU is being extensively practiced by physicians in situations: first, 
when two therapeutic conditions possessing same pathophysiology; second, to treat 
any life-threatening condition where no treatment is available and thereby provide 
off-label use may be proven helpful to patient; and third, drug has not been stud-
ies in specific group or patient age (pediatrics, pregnancy or geriatric). There are 
many examples of drugs which have been prescribed commonly as “off-label” drugs 
(Table 1) [9].
1.3 Orphan diseases and drugs
There is no defined definition for orphan diseases (ODs). In the US it is 
defined as if the disease prevalence affects less than 1 in <200,000, in Japan 
<50,000 and in Australia <2000. WHO defines the prevalence of less than 
6.5–10 in 10,000 [10]. The drug which is used in the treatment of orphan disease 
is referred to as an orphan drug. For example; haem arginate, is being used to 
treat porphyria (acute intermittent, variegate and hereditary), ibuprofen to treat 
patent ductus arteriosus in neonates [11] and N-acetylcysteine for paracetamol 
poisoning. In orphan diseases (ODs) and their management, the count for orphan 
diseases exists approximately 6000 but the efforts that are putting off by phar-
maceutical and R&D sectors for developing new drugs in their management are 
negligible cause the huge amount involved in de novo drug development [12]. Only 
5% of pharmaceutical industries are taking interest in developing new drugs in 
orphan disease management [12]. At present, approximately 325 drugs are avail-
able in the market, which are being used to treat only 5% of orphan diseases. Drug 
Drug Class of drug Approved use Off-label use
Desmopressin Antidiuretic hormone Central diabetes insipidus Nocturnal enuresis
Atenolol, 
propranolol, 
metoprolol
Beta blockers Hypertension Migraine prophylaxis
Imipramine, 
amoxapine
Tricyclic antidepressant Depression Insomnia, Bulimia, 
neuropathic pain 
symptoms
Aspirin NSAIDs Analgesic Antithrombosis in 
atrial fibrillation
Indomethacin NSAIDs Analgesic Closure of patent 
ductus arteriosus
Erythromycin Macrolide antibiotic Haemophilus and Legionella 
infection, whooping cough, 
atypical pneumonia
Gastroparesis
Table 1. 
Examples of off-label drug use (OLDU).
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repurposing provides one of the best faster and economical ways to find new 
treatment options in ODs (Figure 2). To facilitate drug development and treat-
ment options in orphan disease management FDA Orphan Drug Act (ODA) 1983, 
has provided many of the benefits or incentives to pharmaceutical and research 
companies including (i) tax credits (ii) clinical research aids, (iii) fast-track mar-
keting authorization procedures (FDA approval), and (iv) marketing exclusivity 
[13].
2. Approaches for drug repurposing
In drug repurposing, three major steps are involved which consist of (i) 
identification of target candidate for new indication (generation of new hypoth-
esis for new indication or new target), (ii) exploration of mechanism or signaling 
pathway involved in drug or disease and (iii) finally proving the efficacy of drug 
in phase 2 and 3 clinical trials. Among all steps, identification of lead candidate 
is one of the most critical steps. This is the step where the most sophisticated and 
systematic approaches are needed to be implicated for generation of new hypothe-
sis in drug repurposing. Drugs can be repurposed via multiple ways which may be 
either experimentally, clinical based or computationally (Figure 3). Computational 
approach is ‘in silico’ based drug repurposing which is further subclassified as 
either drug-centric or disease-centric. In drug-centric, we find new indications 
for existing drugs while in disease-centric approach, we try new drugs for an 
existing disease.
Figure 2. 
Resource database for orphan diseases (ODs) and drugs.
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2.1 Experimental strategies in drug repurposing
2.1.1 Binding assays to identify target candidate
Techniques like chromatography and mass spectrometry are being used to find 
all possible binding targets of drug candidates. Brehmer et al. conducted a study 
using HeLa cell extract to identify possible protein targets of gefitinib. The results 
of mass spectrometry revealed that the drug can interact with 20 different protein 
kinases which may be treated as possible targets of gefitinib [14].
2.1.2 Phenotyping screening
In the world of drug discovery and development, the term phenotyping screen-
ing is used to describe the ways adopted to identify the biological effects of a drug 
which is either directly or indirectly linked to a disease. With the development of 
robotic and sensitive screening tools, the approach is used to screen thousands 
of chemical drug libraries in a single go. It involves the screening of target drug 
candidates either using cell-based screens (high throughput screening (HTS)) or 
even whole organism [15]. Cell based assays involve cell lines derived from human 
or animals, immortalized cell lines or induced pluripotent cells lines (iPSCs), etc. 
For example, Iljin et al. [16] performed HTS of approximately 5000 small mol-
ecules using prostate cancer epithelial cell lines. In this experiment, disulfiram was 
found to possess selective antineoplastic property which was validated later using 
genome wide gene expression studies [16]. Important cell-based assays that are 
being performed in drug discovery and repurposing include: cell viability assay, 
signaling pathways assay and disease related mechanistic assay. Other cell assays 
Figure 3. 
Approaches for drug repurposing. (a) Experimental based, (b) clinical based and (c) computational based 
drug repurposing.
Drug Repurposing
6
that are being performed routinely in drug development include cell apoptosis, 
infection, cell motility, cell cycle arrest and many more [17]. Cousin et al. [18] 
have used zebrafish model to evaluate the efficacy of compounds against tobacco 
dependence. In this study the authors have found that the agents like apomorphine 
may be useful in modifying nicotine or ethanol induced dependence behavior 
[18]. Over the decades in drug discovery, these approaches are getting shifted 
more toward molecular targets based on phenotypic methods, which rely mainly 
on molecular targets of drugs and diseases and related mechanisms for hypothesis 
generation.
2.2 Clinical perspective
2.2.1 Clinical analysis (human experiments)
Clinical trials providing positive outcomes are quite rare as most of the drugs 
fail during Phase II/III trials. But many drugs which already have been marketed 
during post-marketing surveillance provides different outcome. Some may display 
different adverse events and some may treat specific kinds of disease with no 
labeled indication. Many drugs have been repurposed with the help of these trials. 
Some such examples are apomorphine was indicated for Parkinson’s disease and 
it was repurposed for erectile dysfunction, drospirenone—oral contraceptive and 
repurposed for hypertension, dapoxetine—analgesia and depression and repur-
posed for hypertension [3]. These are very few examples of clinically repurposed 
drugs, there are many such drugs which have been repurposed with many new 
indications [1].
2.3 Computational perspective
2.3.1 Knowledge-based repurposing
This approach is based on already available data such as ligands and recep-
tors. Specific models can be developed in order to locate the targets that have not 
been discovered/explored yet. These models are developed to discover the novel 
bio-markers, pathophysiology and receptors for various diseases. This kind of 
approach could also be beneficial in predicting different adverse reaction related to 
drugs, their structure activity relationships (SAR), ligands targeting the different 
pathways, etc., So, this could be mechanism based, pathway-based, receptor-based 
repositioning of drugs [1].
2.3.2 Target/molecular docking-based drug repurposing
In-silico screening of various compounds by generating drug library could 
find a lead molecule resulting targeted therapies. Drug compounds of specific 
interest from drug libraries can be selected by molecular docking or ligand-based 
screening which incorporates high-throughput screening (HTS) as large number of 
compounds are screened in this method [19]. The other methods include standard 
precision (SP), extra precision (XP).
During this screening there is no incorporation of information related to any 
biological or pharmacological as the screening is blinded. Target-based approach 
links the targets such as any receptor with the pathophysiology behind the disease 
and therefore the process of drug-discovery revamps. Withstanding to this target-
based approach cannot predict the novel/unknown mechanism with the currently 
available targets of the disease [1].
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2.3.3 Pathway mapping/pathway-based drug repurposing
Information such as protein-protein interaction, cell signaling and metabolic 
pathways can be useful for predicting the intersection between disease and drugs. 
The best possible example could be data available from the central database of 
patients can define the pathways involved in the specific disease are possibly recon-
structed for drugs repositioning [19].
2.3.4 Target mechanism-based drug repurposing
Predicting the novel mechanism of action by this approach and resulting in 
drug repurposing for existing drugs. This is possible by gathering information 
from signaling pathway information, interaction networks of various proteins 
and also by data obtained from omics. Additionally, this will contribute to preci-
sion medicine. As, increasingly the individuals with their respective diseases have 
different pathophysiology among them. Precision medicine is upcoming solution 
for all these unique disease specific pathophysiological individuals. Advantages 
for drug repurposing by these approaches can discover not only different patho-
physiological mechanisms but also providing treatment to them with respective 
drugs [19].
2.3.5 Machine learning
Machine learning (ML) techniques such as deep learning (DL), gradient boosted 
machine with trees (GBM), random forest (RF), support vector machine (SVM), 
logistic regression with elastic net regularization (EN), deep neural networks 
(DNN) have been usually applied for repositioning of various drugs [20, 21].
2.3.6 Network models
The various interaction patterns such as protein-protein, drug-disease, disease-
gene, drug-target, drug-drug, disease-disease and transcriptomes and cell signaling 
networks are usually procured from different databases, which are interpreted com-
putationally. The network models represent each and everything like drug, disease, 
gene and related products and their interaction patterns, for example, nodes (drug, 
disease and genes) and edges (interaction patterns of nodes). Network models 
are divided in to two types, these includes: network-based cluster approaches and 
network-based propagation approaches [19].
2.3.6.1 Network-based cluster approaches
These kinds of approaches have been proposed in order to determine the mecha-
nism/relationships between the drug and the disease or the drug and the target/
receptor. The biological interaction pattern in our human body has a characteristic 
network. The entities such as disease, drug and the protein share similar kind 
of interaction pattern in the network-based cluster approaches. This approach 
has been incorporated to develop various kinds of modules using the network 
topology-based cluster algorithms  such as cliques/clusters/groups, subnetworks. 
They portray relationships or pattern of interaction between drug-drug, disease, 
target/receptors. The overlapping clusters cannot be detected by CLIQUE, OPTICS, 
DBSCAN and STING [20]. These modules are most commonly used network-based 
cluster approaches. Examples of repurposed drugs using network approach are 
atomoxetine indicated for Parkinson’s disease and repurposed for attention deficit 
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hyperactivity disorder (ADHD), etanercept indicated for rheumatoid arthritis and 
repurposed for asthma [3].
2.3.6.2 Network-based propagation approaches
These approaches have been categorized as another important approach 
under network strategies. They can be classified in two types: local and global 
approach. The information under this approach circulates from node (source) 
to all the nodes which are networked to each other and followed by subnetwork 
nodes [19].
Many studies have stated that these techniques are really being helpful and pro-
viding some useful results in obtaining interaction patterns/relationships between 
the drug—target/receptor, gene, disease. Local propagation procures small/fewer 
amount of data from the database and displays improper results. In opposing to this 
global approach gathers all of the data from database/network and make correct 
predictions. Currently, researchers are working on global approach for drug repur-
posing/repositioning [1, 19].
2.3.7 Genetic association
Genome-wide association studies (GWAS) has been widely used to determine 
the genetic alterations in whole genome which contribute to specific diseases and 
provides the pathophysiology of various diseases. The data obtained from the 
GWAS helps to identify novel targets which contributes to the specific diseases 
can provide repositioning of several drugs. Human Genome Project has already 
been completed and vast amount of data is available for specific diseases. So, there 
is a huge opportunity for various drugs that could be repositioned and provide 
beneficial outcome. However, the data available from GWAS does not provide exact 
pathophysiological mechanism and the available data is not appropriate due to 
the gene variant. As, there many still thousands of genes hidden which is yet to be 
discovered and these hidden genes may be contributing largely behind pathophysi-
ology of various diseases [1].
2.3.8 Signature-based repurposing
Signature inversion method is defined as the approaches which screens the 
inverse relationships/interaction pattern of drug and the disease by correlating the 
gene expression information between the drug-disease. As defined this method 
utilizes the expression of genes to discover off-target mechanisms as well as novel 
pathophysiological mechanisms related to diseases. One of the prime advantages of 
these approaches is that they identify unique/novel mechanisms of action for drugs. 
Additionally, unlike knowledge-based methods that use the databases to predict the 
mechanism or action of drugs, more molecular- and/or genetic-level mechanisms 
are involved in signature-based repurposing methods [1].
2.3.9 Text mining (data mining) and semantic approach
The data available in the literature contains large and varied amount of infor-
mation/data for all the drugs in the database as well as for the diseases (including 
orphan/rare diseases) which are commonly occurred in individuals. Through these 
data one can potentially predict the new indications of existing drugs via text min-
ing approach. Gene ontology/biological ontology allows us to correlate the available 
information and analyze all the biological data from different databases. One such 
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example of repurposed drug is Everolimus indicated for immunosuppressant and 
repurposed for pancreatic neuroendocrine tumors [3].
Semantic inference incorporates techniques like topic modeling which utilizes 
different databases for the discovery of repurposing of existing drugs. Example of 
repurposed drug was amphetamine which was indicated for CNS stimulant and 
repurposed for hyperkinesis in children (ADHD) [3].
3. Drug repurposing/repositioning for orphan diseases/disorders
Approximately 7000 rare diseases are currently present in the world and more 
than 95% among these lack therapeutic agents approved by US-FDA [1]. The con-
cept behind orphan disease might be many yet they have a single key point which 
is common that is the disease affects a minor part of the population. The definition 
of orphan diseases differs in different countries. In US, orphan disease is the one 
affecting fewer than 2 lakh people, in Japan the disease should affect fewer than 
50,000 people to be called as orphan disease and in Europe the prevalence should 
be 5 in 10,000 [1, 22].
It is very challenging to develop new drugs for the treatment of rare diseases 
because the number of patients suffering from these diseases are very limited 
and are distributed over a vast geographical area. Another issue is of high vari-
ability among these diseases, influenced mostly by genetic factors. Financially, 
the development and subsequent production of these drugs is not viable for the 
pharmaceutical companies therefore drug repurposing for orphan diseases is a 
good option [22]. The patients requiring immediate treatment also do not have the 
luxury of more time at their disposal therefore a new strategy is needed so that the 
drugs are made available faster and cheaper to these patients. The pathology and 
various biochemical pathways of many orphan diseases are not very well known. 
Computational techniques will be a helpful option in the case where the underlying 
mechanism of the disease is not well understood. The advancement of the huge 
scale genomic sequencing project may lead to the understanding of the genetic 
variations that may be the cause of these diseases and it may lead to possibility of 
repurposing the drugs which are targeting the concerned protein [1]. There are few 
examples of repurposed drugs described in Table 2.
The approved drugs have already undergone intense testing like the safety stud-
ies, bioavailability studies and PK/PD studies and therefore drug repurposing leads 
to significant cost cutting and faster development [22]. Hence, this is an attractive 
prospect for the pharmaceutical industry as well. A total of 51 new medications 
reaching the market in 2009, the drugs which came to the market via the strategy of 
drug repurposing were 30% [23].
There are particular regulations designed to promote the research into orphan 
diseases and these rules could give market exclusiveness in circumstances repur-
posed agents cannot be protected by the patent. The Orphan Drug Act (ODA; 1983) 
was introduced for the first time which reflected the issues regarding the econom-
ics of drug development for orphan disease and how it was unfavorable. FDA has 
licensed about 360 agents for rare diseases since 1983 as compared to less than 50 
agents before 1983 [24]. US legislation provides for faster FDA approval, tax incen-
tives and funding support for research in orphan diseases. Market protection is also 
one of the incentives in which a generic form is not allowed to come to the market for 
7 years. Tax concession, waiving of the regulatory fees are also the incentives which 
are provided. Similar legislation has been implemented in Singapore, Japan, Europe 
and Australia after the success of ODA, with each jurisdiction having a little bit of 
difference in the definition of the indication and the incentives to be provided [1].
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Another area of concern is the broad group of infectious diseases known 
to affect more than 1 billion population in tropical and subtropical areas [22]. 
Populations that are severely impacted are the people living below poverty line, 
not having appropriate sanitary conditions and in direct contact with contagious 
vectors or domestic animals [25]. The therapies currently present have many draw-
backs like pricing and increase probability of drug resistance. Moreover, there are 
not much financial gains for investing money in developing drugs for these diseases 
as the patient population is unable to afford them [26]. Subsequently, given that the 
profit-making companies produce almost all the drugs, these firms will hardly be 
having any interest in investing in drug research and development which will not 
produce high financial returns. For this reason, development of therapies for these 
diseases becomes increasingly necessary. As discussed earlier that drug repurposing 
is an effective method due to various reasons, it can also be effectively used in this 
area where resources are limited and there is a huge need for productive therapies. 
Miltefosine, used for visceral leishmaniasis originally was antineoplastic agent 
whereas Amphotericin B used to treat fungal infections was repurposed for treating 
visceral leishmaniasis [22]. Other examples include Tamoxifen (agent for breast 
cancer) has shown to have anti-leishmanial activity, eflornithine (topical agent for 
hirsutism) has shown to be effective for sleeping sickness and auranofin (drug for 
rheumatoid arthritis) has shown to be effective against lymphatic filariasis and 
Onchocerca volvulus induced river blindness [27].
These days, multiple researches have demonstrated encouraging results in terms 
of repositioning supported by computational methods like chemical genomics 
screening for developing agents for such kind of diseases like schistosomiasis [28]. 
Some other examples where drug repurposing has shown promise for these diseases 
are vandetanib, trametinib and atorvastatin [29, 30].
Drug Original indication New indication
Thalidomide Morning sickness Erythema nodosum leprosum and multiple 
myeloma
Sildenafil Angina Erectile dysfunction
Minoxidil Hypertension Hair loss
Zidovudine Cancer HIV/AIDS
Celecoxib Pain and inflammation Familial adenomatous polyps
Atomoxetine Parkinson disease ADHD
Aspirin Analgesia Colorectal cancer
Ketoconazole Fungal infections Cushing syndrome
Topiramate Epilepsy Obesity
Dapoxetine Analgesia and depression Premature ejaculation
Raloxifene Osteoporosis Breast cancer
Rituximab Cancers Rheumatoid arthritis
Duloxetine Depression Stress urinary incontinence.
Fingolimod Transplant rejection Multiple sclerosis
Bupropion Depression Smoking cessation
Lidocaine Local anesthetic Arrhythmia
Table 2. 
A few examples of repurposed drugs with their new indication.
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Drug repurposing strategies have also been used in the cases of viral diseases like 
Zika virus where FDA approved drug for hepatitis C which is Sofosbuvir has shown 
promising results [22]. The target of this drug is RNA polymerase which is present 
in Hepatitis C and Zika virus and has shown to reduce viral load in experimental 
studies [31, 32]. The same is the case with prochlorperazine by targeting the binding 
and the entry of the virus to host cells has shown to have a strong antiviral activity 
against dengue virus [22].
Drug repurposing is cheaper and faster than the conventional methods and thus 
gives hope to the patients where the population suffering from the disease is much 
smaller and making the traditional model of drug discovery nonviable. A collective 
effort is required among all the stakeholders if already available drugs have to be 
repurposed. This approach helps in reducing the potential risks and the expense 
of developing a new agent, therefore having the ability of revolutionizing the drug 
market of orphan diseases.
4. Regulatory considerations for drug repurposing
In the US, to get permission for drug repurposing, research and pharma compa-
nies need to file applications under suitable sections including 505(b)(1), or 505(b)
(2) or 505(j), depending upon the regulatory paths. Further, the company needs to 
fill NDA type 6 and sNDA (supplemental new drug application) for new indication 
of drug, NDA type 3 for new dosage form and NDA type 4 for drug new combina-
tion in drug repurposing [1, 33].
5.  Future perspectives of drug repurposing in orphan disease 
therapeutics
As orphan disease affects a small percentage of the population, research and 
pharma companies face great challenge and burden in developing drugs for its man-
agement because of small market potential. Patients fail to get proper care, diagno-
sis and treatment. Even if the treatment is available, it is relatively expensive. Thus, 
drug repurposing can be of great help in orphan disease therapeutics. It saves both’ 
the time and money involved in the drug development process. In October 2010, 
“Dr Ruxandra Draghia-Akli, the Directorate-General for Research and Innovation 
(DG RTD) of the European Commission (EC) and Dr Francis Collins, US National 
Institutes of Health (NIH)” at Reykjavík (Iceland), launched the International 
Rare Diseases Research Consortium (IRDiRC) to look after the drug and research 
development in orphan/rare diseases [34]. This consortium unites both government 
and private research funding societies to advance the drug development for orphan 
diseases at global level including task forces and drug repurposing in orphan disease 
therapeutics.
The research in rare diseases has already changed the global approach because 
earlier researchers were not much interested in repurposing the existing drug but 
some global breakthrough has really changed the minds of pharma companies 
and examples are alglucerase that was obtained from human placental tissue 
and was widely used for Type I Gaucher disease as a “first enzyme replacement 
therapy” and, it was also approved by FDA in 1991. However, it was withdrawn 
from the market due to adverse effect and already available drugs in the market 
which are prepared from recombinant DNA technology which are safe to use [35]. 
Fomivirsen which is an antisense oligonucleotide and was approved by FDA for 
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Cytomegalovirus in 1998 but it has been withdrawn from the market due to the 
development of highly active antiretroviral therapy (HAART) but this was the “first 
antisense oligonucleotide therapy” [35]. Imatinib was approved by FDA in 2001 for 
Philadelphia chromosome-positive chronic myelogenous leukemia (CML) as “first 
targeted cancer therapy” [35]. Alipogene tiparvovec was the “first targeted gene 
therapy” to be approved in Europe in 2012 for reversing lipoprotein lipase defi-
ciency (LPLD) in patients with pancreatitis [35]. Strimvelis was the “First ex-vivo 
gene therapy” approved for patients with Severe Combined Immunodeficiency 
due to Adenosine Deaminase deficiency (ADA-SCID) [35]. USFDA has approved 
Holoclar as orphan drug for the treatment of limbal stem cell deficiency (LSCD). 
Currently, this drug is in Phase IV trial and completing in mid of the year 2020 [36].
To overcome R&D-associated financial challenges and clinical trials-related 
failures of novel drugs, at present scenario, pharmaceutical companies are much 
more interested in switching to “drug repurposing” or “drug repositioning” drug 
development by adopting various computational approaches rather than going for 
de novo drug discovery, which is relatively expensive, risky and time consuming 
[37]. According to Southall et al. [35], the global market for drug repositioning will 
possibly be hiked to over $31 billion by 2020, up from about $24 billion in 2015, thus 
representing large commercial possibility [35].
6. Conclusion
De novo drug development is being time consuming, costly and risk-prone ven-
ture ‘drug repurposing’ has drawn attention of all pharma companies and R and D 
sectors which offers faster and cheaper ways for bringing new drugs into the market 
especially for targeting ODs. Based upon the benefits provided by drug repurpos-
ing, the development of more sophisticated and systematic approach is required to 
find more drug candidates that can be fitted into the picture of promising targets 
for repurposing.
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